Semaglutide The SUSTAIN-6 (trial to evaluate cardiovascular and other long-term outcomes with semaglutide in subjects with type 2 diabetes) was a double-blind trial in which T2D patients were randomized to receive either 0.5 or 1.0 mg of once-weekly subcutaneous semaglutide or placebo (Marso et al., 2016a)
Immun Ageing 21(1):30 Waseem R, Shamsi A, Mohammad T, Hassan MI, Kazim SN, Chaudhary AA, Rudayni HA, Al-Zharani M, Ahmad F, Islam A (2022) FNDC5/irisin: physiology and pathophysiology
The full TRIUMPH program data, expected to complete this year, will provide a more comprehensive picture of how these two compounds compare across different populations and treatment durations
It may be considered for individuals who are sensitive to higher doses or want to potentially minimize side effects
Rapid weight loss itselfa common outcome with GLP-1 therapymay impact ovulation regularity and hormonal balance in ways that are still being researched
Vyvanse for Binge Eating: Also Considering Wegovys Role Addressing binge eating disorder (BED) requires a multifaceted approach, and Vyvanse has emerged as a viable pharmacological option in this domain
